Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Biochemical Society Transactions|January 11, 2023
Therapeutic targeting of TRAIL death receptorsFrancesca Di Cristofano, Andrew George, Vida Tajiknia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2022
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma modelsGilles Berger, Erik H Knelson, Jorge L Jimenez-Macias, et al.
Clinical Colorectal Cancer|September 25, 2020
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal CancerArthur Winer, Crystal S Denlinger, Namrata Vijayvergia, et al.
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cellsLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Oncotarget|November 27, 2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infectionLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
The Journal of Clinical Investigation|July 15, 2024
Targeting apoptotic pathways for cancer therapyXiaobing Tian, Praveen R Srinivasan, Vida Tajiknia, et al.
Cell Cycle (Georgetown, Tex.)|November 22, 2017
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignanciesVarun V Prabhu, Mala K Talekar, Amriti R Lulla, et al.
Neoplasia (New York, N.Y.)|November 3, 2020
ONC201 and imipridones: Anti-cancer compounds with clinical efficacyVarun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, et al.
The Journal of Clinical Investigation|January 14, 2025
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injuryJillian Strandberg, Anna Louie, Seulki Lee, et al.
Pageof 11